Ceryvyn Therapeutics Limited (ASX:CYV)
Australia · Delayed Price · Currency is AUD | Market Cap | 13.68M -98.1% |
| Revenue (ttm) | 1.00K -99.6% |
| Net Income | 330.45M |
| EPS | 0.24 |
| Shares Out | 1.37B |
| PE Ratio | 0.04 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,165 |
| Open | 0.0110 |
| Previous Close | 0.0100 |
| Day's Range | 0.0100 - 0.0110 |
| 52-Week Range | 0.0080 - 0.0250 |
| Beta | 1.48 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 26, 2026 |
About Ceryvyn Therapeutics
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia. [Read more]
Financial Performance
Financial StatementsNews
Ceryvyn Therapeutics Earnings release: Q1 2027
Ceryvyn Therapeutics released its Q1 2027 earnings on October 28, 2026, summarizing the period's financial results.
Ceryvyn Therapeutics Annual report: H2 2026
Ceryvyn Therapeutics has published its H2 2026 annual report on August 30, 2026.
Ceryvyn Therapeutics Transcript: Investor update
A rare disease-focused biotech is advancing OPT-302 for LAM, supported by strong cash reserves, a rigorous stage-gated clinical plan, and leading scientific advisors. The company is committed to transparency, disciplined execution, and shareholder value, with sufficient funding for its 18-month program.
Ceryvyn Therapeutics Slides: Investor update
Ceryvyn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Ceryvyn Therapeutics Slides: Investor presentation
Ceryvyn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Ceryvyn Therapeutics Earnings release: Q3 2026
Ceryvyn Therapeutics released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Ceryvyn Therapeutics Quarterly report: H1 2026
Ceryvyn Therapeutics has published its H1 2026 quarterly earnings report on February 28, 2026.
Ceryvyn Therapeutics Slides: Corporate presentation
Ceryvyn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on December 16, 2025.
Ceryvyn Therapeutics Transcript: AGM 2025
The AGM covered director re-elections, adoption of the remuneration report, and approval of option grants, with all resolutions put to a poll and no questions raised by shareholders. Voting results will be published post-meeting.
Ceryvyn Therapeutics Earnings release: Q1 2026
Ceryvyn Therapeutics released its Q1 2026 earnings on October 29, 2025, summarizing the period's financial results.
Ceryvyn Therapeutics Annual report: H2 2025
Ceryvyn Therapeutics has published its H2 2025 annual report on August 29, 2025.
Ceryvyn Therapeutics Annual report: H2 2025
Ceryvyn Therapeutics has published its H2 2025 annual report on August 29, 2025.
Ceryvyn Therapeutics Transcript: Investor Update
Phase III trials failed to show efficacy for sozinibercept in wet AMD, leading to program termination and a settlement with investors that leaves the company with $20 million cash and no debt. A strategic review is underway to explore internal and external opportunities, with updates expected later this year.
Ceryvyn Therapeutics Press release: Investor Update
Ceryvyn Therapeutics issued a press release on August 19, 2025, disclosing material business information to investors.
Ceryvyn Therapeutics Slides: Investor Update
Ceryvyn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2025.
Opthea Provides Corporate Update
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to contin...
Ceryvyn Therapeutics Earnings release: Q4 2025
Ceryvyn Therapeutics released its Q4 2025 earnings on July 29, 2025, summarizing the period's financial results.
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
Ceryvyn Therapeutics Press release: Study Result
Ceryvyn Therapeutics issued a press release on March 23, 2025, disclosing material business information to investors.
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Ceryvyn Therapeutics Quarterly report: H1 2025
Ceryvyn Therapeutics has published its H1 2025 quarterly earnings report on February 27, 2025.
Ceryvyn Therapeutics Earnings release: H1 2025
Ceryvyn Therapeutics released its H1 2025 earnings on February 27, 2025, summarizing the period's financial results.
Ceryvyn Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Sozinibercept, a VEGF-C/D trap, is advancing through Phase 3 trials for wet AMD, targeting improved vision outcomes in combination with anti-VEGF-A agents. Pivotal data readouts are imminent, with strong market, payer, and physician support, and a potential FDA approval by late 2026.
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...